Emerging analgesic drugs for Parkinson's disease (Q38005224)

26 August 2017

Emerging analgesic drugs for Parkinson's disease (English)

1 reference

26 August 2017

1 reference

Christine Brefel-Courbon

5

object named as

Christine Brefel-Courbon

1 reference

26 August 2017

6

Olivier Rascol

1 reference

26 August 2017

Santiago Perez-Lloret

1

object named as

Santiago Perez-Lloret

1 reference

26 August 2017

María Verónica Rey

2

1 reference

26 August 2017

Estelle Dellapina

3

1 reference

26 August 2017

Jean Pellaprat

4

1 reference

26 August 2017

language of work or name

English

0 references

publication date

25 April 2012

1 reference

Expert Opinion on Emerging Drugs

26 August 2017

1 reference

26 August 2017

17

1 reference

26 August 2017

157-171

1 reference

26 August 2017

2

1 reference

The need for neuroprotective therapies in Parkinson's disease: a clinical perspective

26 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Cost of disorders of the brain in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Parkinson's disease. First of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

The importance of non-motor disturbances to quality of life in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Clinical management of pain and fatigue in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Pain in Parkinson's disease: Prevalence and characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Radicular and nonradicular back pain in Parkinson's disease: a controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Pain in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Pain is common in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Quality of life and pain in Parkinson's disease: a controlled cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Neurophysiologic study of central pain in patients with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Abnormal processing of the nociceptive input in Parkinson's disease: a study with CO2 laser evoked potentials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Spontaneous pain, pain threshold, and pain tolerance in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

The relationship of pain and health-related quality of life in Korean patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Pain perception, pain drug therapy and health status in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

The pathophysiological basis of sensory disturbances in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Clinical advantages of COMT inhibition with entacapone - a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Dopamine agonist withdrawal syndrome in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Administration of levodopa for relief of herpes zoster pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Levodopa analgesia in experimental neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Levodopa in the treatment of Parkinson's disease: current controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Burning mouth syndrome responsive to pramipexol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Subcutaneous apomorphine in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Comparison of chronic analgesic drugs prevalence in Parkinson's disease, other chronic diseases and the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Pain in Parkinson's disease: analysis of 50 cases in a clinic of movement disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Duloxetine: a review of its pharmacology and use in chronic pain management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Chronic subthalamic deep brain stimulation improves pain in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Influence of deep brain stimulation and levodopa on sensory signs in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Subthalamic nucleus stimulation for attenuation of pain related to Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Features associated with the development of non-motor manifestations in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Intractable facial pain in advanced Parkinson's disease alleviated by subthalamic nucleus stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Motor and nonmotor symptom follow-up in parkinsonian patients after deep brain stimulation of the subthalamic nucleus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Effect of deep brain stimulation on pain in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Unilateral pallidotomy for reduction of parkinsonian pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Interventional neurophysiology for pain control: duration of pain relief following repetitive transcranial magnetic stimulation of the motor cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Transcranial magnetic stimulation applications and potential use in chronic pain: studies in waiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Pain relief induced by repetitive transcranial magnetic stimulation of precentral cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Transcranial magnetic stimulation for pain control. Double-blind study of different frequencies against placebo, and correlation with motor cortex stimulation efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

French guidelines on the use of repetitive transcranial magnetic stimulation (rTMS): safety and therapeutic indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

rTMS for suppressing neuropathic pain: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Longlasting antalgic effects of daily sessions of repetitive transcranial magnetic stimulation in central and peripheral neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Functional MRI of the immediate impact of transcranial magnetic stimulation on cortical and subcortical motor circuits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Motor cortex stimulation in neuropathic pain. Correlations between analgesic effect and hemodynamic changes in the brain. A PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Invasive brain stimulation for the treatment of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Motor cortex stimulation for pain control induces changes in the endogenous opioid system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Placebo-controlled study of rTMS for the treatment of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Effect of low-frequency repetitive transcranial magnetic stimulation combined with physical therapy on L-dopa-induced painful off-period dystonia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

The amelioration of the suffering associated with spinal cord injury with subperception transcranial electrical stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Pain reduction using transcranial electrostimulation: a double blind "active placebo" controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Systematic review of incidence studies of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Prevalence and incidence of Parkinson's disease in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Naloxone-responsive acute dystonia and parkinsonism following general anaesthesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Tramadol hydrochloride use and acute deterioration in Parkinson's disease tremor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Assessing the impact of pharmacologic intervention on the quality of life in diabetic peripheral neuropathic pain and fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Clinical Effectiveness and Cost-Effectiveness of Treatments for Patients With Chronic Pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an 8-week treatment course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

The mechanism of action of aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

The analgesic efficacy of intrathecal D-Ala2-D-Leu5-enkephalin in cancer patients with chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Core outcome measures for chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Psychiatric aspects of Parkinson's disease--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

Apathy and depression scales in Parkinson's disease: are they good enough?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2012.677949

10.1517/14728214.2012.677949

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference